How sweet it is: Coca-Cola and BNDES shower projects with funding in Brazil; larger sugarcane harvests in the forecast

Droughts have plagued North America cutting corn output to a 16-year low, while monsoon rainfall has been 12% lighter in areas of India and even more in other regions. But in Brazil, even though excessive rains pushed harvesting back, the 2012 yield still rose to 571 million metric tons. Estimates peg next year’s crops as being bigger than ever, due to the same unusually rainy conditions. The harvest season ending in 2010 saw yields of 541 million, and in 2011 yields grew slightly, to 557 million metric tons. But next year’s yield is being forecast to be even larger – 5.4% larger – at 602 million metric tons.

Also in Brazil, Coca-Cola contracted JBF Industries to produce ethylene glycol in Araraquara, Sao Paulo, for partially bio-based PlantBottle PET. JBF will build a new plant starting at the end of 2012 and will produce 500,000 metric tons/year; it will take two years to complete.

But aside from the feedstock and materials developments, there’s money flowing, too, in Brazil. Brazilian national development bank, BNDES, and research-financing agency, Finep, have earmarked $988 million for bio-based chemicals and biofuels investment to be placed this year ($148 million), 2013 ($345 million), and 2014 ($493 million). They emphasize only “several projects” will be pursued. Dow Chemical, Braskem, and DuPont each passed the initial selection phase for their proposals to build projects collectively worth more than $1.5 billion. DSM has already been approved to receive funding for succinic acid from sugarcane. Previously, the two organizations contributed $493 million to research on cellulosic ethanol production, gasification, and other value-added derivatives of sugarcane.

For any that doubt, Brazil’s sugarcane continues to put it on the map of bio-based chemicals and biofuels production hotspots, although a recent conversation highlighted that, ironically, corn was less exposed to food price increases than sugarcane, since sugarcane prices track with sugar, a commodity more tightly linked to food price trends than corn, which is largely used for feed and ethanol. Brazilian government support for sugarcane production and downstream conversion activities is strong, and the Brazilian bio-chemical industry has a reputation for translating technology into commercial successes well. Whether it be to keep tabs on a formidable competitor or to understand the landscape in Brazil to explore forming a valuable partnership to secure feedstock or to access sugarcane-derived material, clients are advised to monitor Brazil’s sugarcane harvest and consider it when making decisions about feedstock supply. Though this year’s droughts are not expected to repeat next year, contingency plans for less likely – and even more unlikely events – are advised, as volatility in weather yields volatility in crop yields.

Amyris’s Shake up: A True Housecleaning or Sign It’s Desperate to Partner to Grow Demand?

Just days before its quarterly earnings call this month, Amyris sparked a sell-off of its stock when it announced that President and CEO John Melo would keep his job as three other executives leave: Mario Portela, former President of Global Operations and COO; Tamara Tompkins, former Executive Vice President, General Counsel, and Corporate Secretary; and Neil Renninger, former Chief Technical Officer. We interviewed Neil for Lux’s recent profile of Amyris (Client registration required), just before the announcement of back-peddling on earnings and production targets. Neil will remain a member of Amyris’s Board of Directors, which isn’t a surprise since he was among the original co-founders.

In addition to the departures, several other executives will change positions or join Amyris. Highlights include Peter Boynton, formerly of Tate & Lyle – one of Amyris’s partners – and who’s been with Amyris since late 2009, will now lead business development (See the report, “Solving the Bio-Based Chemicals Partnership Puzzle.” Client registration required.). Paulo Diniz, who has been leading Amyris Brasil, will add strategic partnerships to his responsibilities. Gary Loeb, eleven-year veteran of Genentech before joining Amyris in mid-2011, will take the lead as Amyris General Counsel and Corporate Secretary. Steve Mills brings three decades of experience at ADM to his new role as Chief Financial Officer. Mark Patel shifts from VP of Strategy to Senior VP of Commercial Operations, concerned with products strategy and sales growth. Ramesh Raman was promoted from VP Global Supply Chain Operations to Senior VP of Global Manufacturing, responsible for manufacturing and supply chain.

In light of Amyris’s recent changes in earnings and production guidance, it’s no secret things need to change there. But no evidence of show-stopping technical challenges exists. Given that, a drastic management shake-up is not warranted, if the existing team can accelerate demand growth.

In addition, what’s striking about this “shake-up” is how little it changed things. Minor alterations to titles and “promotions” from VP to Senior VP. The exits of the former COO, CTO, and General Counsel and addition of the ADM veteran CFO reflect housekeeping rather than full house-cleaning on the part of CEO Melo and the Board. Melo retains the Board’s support, taking an approach of scapegoating a few, rather than starting from scratch and reflects no decisive change in strategy – except to focus on growth.

Though Amyris could potentially be the next casualty in the unquestionably harrowing world of bioproduct commercialization, the Board may realize in the face of possible bankruptcy it should allow Melo to focus on growing demand, rather than hiring another management team. Adjusting to more austere times and doing the hard work of increasing demand is the new normal for Amyris, and this may be the best time to invest with an equity stake and partner with Amyris, ever. The question remains, however: Can Amyris build or access sufficient markets to bring in substantial revenue with its farnesene-based platform?

Rating Thermochemical Start-ups on the Lux Innovation Grid

Small technology startups are driving a wave of new bio-based chemicals and materials technologies, and their growth is catalyzing the biggest change the global chemicals industry has seen in decades. In a recent report (client registration required), Lux Research applied its Lux Innovation Grid to rate 106 startups competing in seven technology areas, ranging from renewable feedstocks like algae, GM crops, and waste gases, to downstream processing in pyrolysis, gasification, and synthetic biology.

This week’s graphic displays the likely winners and losers who are fielding thermochemical processes, which promise the bounty of bioprocessing without the need for engineered microbugs. Unlike bioprocessing, thermochemical technologies create compounds via more scalable catalytic and conventional chemical methods. The Dominant quadrant’s five innovators make the field one of the strongest in the bio-based chemicals and materials space.

Among the top innovators is Elevance, which uses metathesis to convert plant oils into glycerin, esters, and biofuels. Its high Technical score derives from its simple chemical process and capital-light manufacturing, which combine to yield a disruptive process. But Elevance also has ongoing collaborations with Cargill, Materia, Dow Corning, Tetramer Technologies, Stepan, Wilmar International, and others, all of which fueled the company’s $100 million IPO filing.

Also in the Dominant quadrant is Virent, which develops fuels and chemicals from soluble sugars. It rates highly on Business Execution because of its management team’s industrial and scientific backgrounds and investments from Cargill, Honda, and Shell. Moreover, the company has a partnership with HCL Cleantech, which supplies cellulosic sugars. Its technology signifies a unique and effective way to convert sugars to alkanes that may then be catalytically converted to a slew of materials (client registration required).

Both Red Lion Bio-energy and Siluria occupy the High Potential quadrant, but that’s about all the two companies have in common. Red Lion, whose process combines aspects of pyrolysis and gasification to convert biomass to syngas, faces business challenges because its gasification technologies are capital-intensive. Meanwhile, Siluria Technologies has a unique catalyst support technology designed to efficiently convert natural gas (fossil or biogas) to ethylene. While its approach is notable and potentially very valuable, the company is only in its fourth year and has not made much commercial progress yet. It has raised about $17 million in venture funding to date, but it lacks chemical industry connections through management experience or partnerships.

Source: Lux Research report “Assessing Innovator Evolution in Renewable Materials and Chemicals.”